Precigen Q3 net loss $7.6M; cash $153.8M; retired $144M convertible notes

PRECIGEN, INC.

2022-Q3 EPS reported $0.25 revenue$25,146,000

Net loss from continuing ops $7.6M ($0.04/sh) vs $26.3M loss; total revenues up $13.4M (>200%) YoY.
Cash, equivalents, short-term investments and restricted cash totaled $153.8M as of Sep 30, 2022.
Retired $144M of $200M convertible notes due July 2023 at a discount; realized $5.4M savings.
Clinical: Phase 1 enrollment complete for PRGN-2012 in RRP; virtual R&D event Jan 2023; ASH presentations.
Phase 1b expansion for PRGN-3006 at Mayo Clinic; first patient dosed; FDA clearance for repeat dosing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECIGEN, INC. reported financial results for third quarter 2022.

Period: third quarter 2022
Result: reported results

Exact text from the filing

precigen reports third quarter 2022 financial results and progress of clinical programs

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-22-019454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.